...chairs its SAB. Bishop was CSO at Otonomy Inc. (NASDAQ:OTIC) and previously held roles at Tioga Pharmaceuticals Inc....

...CR845, a KOR agonist, in Phase III and Phase II testing, respectively, to treat pain. Tioga Pharmaceuticals Inc....

...steps could include testing the biased KOR agonist in additional models of pain and itch. Tioga Pharmaceuticals Inc....

...compared with vehicle. Next steps could include testing KOR agonists in additional models of MS. Tioga Pharmaceuticals Inc....

...evaluate 5 mg oral asimadoline daily for up to 8 weeks in about 200 patients. Tioga Pharmaceuticals Inc....

...Urso as SVP of corporate development and general counsel, formerly COO and general counsel at Tioga Pharmaceuticals Inc. WIR...

...is being developed for chronic use, so it does not require retreatment data. Behind Xifaxan, Tioga Pharmaceuticals Inc....
...Amsterdam, the Netherlands PPD LLC , Wilmington, N.C. Salix Pharmaceuticals Inc. (NASDAQ:SLXP), Raleigh, N.C. Tioga Pharmaceuticals Inc....

...opioid receptor agonists for pain associated with GI indications, though not for use during colonoscopy. Tioga Pharmaceuticals Inc....
...Morrisville, N.C. gIcare pharma Inc. , Montreal, Quebec Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Tioga Pharmaceuticals Inc....

...opioid receptor delta 1 ( OPRD1 ; DOR) antagonist that is in Phase III testing. Tioga Pharmaceuticals Inc....
...Ono Pharmaceutical Co. Ltd. (Tokyo:4528; Osaka: 4528), Osaka, Japan Theralpha S.A.S. , Sophia Antipolis, France Tioga Pharmaceuticals Inc....